Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report

Overview of attention for article published in Journal of Medical Case Reports, May 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#15 of 3,928)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 16 news outlets

patent: 2 patents

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 46 Mendeley

Summary News Patents Dimensions citations

So far, Dimensions has found 8 publications that cite this research output.

8

The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.

Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma

Article in Journal of Cancer Research and Clinical Oncology (November 2021)

Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma

Article in Clinical Lymphoma Myeloma & Leukemia (October 2021)

Tafasitamab: First Approval

Article in Drugs (September 2020)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.